Hormonal
Off-label use of topiramate and/or metformin achieves clinically significant preoperative weight loss (>8% total body weight loss) in patients with BMI ≥50 kg/m2 who fail standard bariatric nutritional prescriptions due to dysregulated appetite.
If you have a BMI over 50 and are waiting for bariatric surgery but struggle with hunger and cravings despite dieting, ask your doctor about off-label use of generic Topiramate or Metformin. These drugs can help suppress appetite and facilitate the weight loss needed to make surgery safer and more successful, often at a fraction of the cost of newer branded drugs.
Each patient was prescribed metformin and/or topiramate in an off-label manner in conjunction with lifestyle modifications and achieved >8% total body weight loss during the preoperative period.
Why this rating
Case report series with no control group; high risk of bias and low generalizability.
Source
Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery
Cetin Sari et al. · Frontiers in Endocrinology · 2021
DOI 10.3389/fendo.2021.588016
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →